The Global CEO Initiative on Alzheimer’s Disease (CEOi)

Share:

CEOi

The Global CEO Initiative on Alzheimer’s Disease (CEOi), founded in 2013, is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer’s. The CEOi believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. It is convened by UsAgainstAlzheimer’s.

TwitterLinkedIn

Our members and collaborators

AARP
Abbvie
AC Immune
Alzheimer's Disease International Logo
Anavex logo
Bank of America
Biogen
Cerecin
Cognito Therapeutics
Eisai
GAP Logo
Home Instead Senior Care Logo
Janssen United States Logo
K2 medical research
Lilly Logo
Merck
Neurovision Logo
OECD Logo
Optum Labs
Otsuka in the U.S. Logo
Prothena
Roche Logo
World Economic Forum
World Health Organization

Lessons and Opportunities for the Alzheimer’s Community

Reflections on COVID-19

COVID-19 efforts provide powerful insights that can guide cross-sector responses to the dementia crisis. The Global CEO Initiative on Alzheimer’s Disease, Alzheimer’s Disease International and Hoffmann-La Roche wrote this report to stimulate discussion about how our world can apply these lessons to address Alzheimer’s disease: the growing pandemic.

Read Report

 

A new podcast on stopping Alzheimer’s: A growing pandemic

Download CEOi’s new podcast series on how to end Alzheimer’s disease – a growing pandemic and one of the world’s most serious unmet health needs. As explained by the experts in this podcast, transparency, smart policy, and close collaboration can help stop the devastation Alzheimer’s unleashes on patients, families, health systems and entire economies.

In this episode, current and former regulatory officials take a page from the COVID-19 playbook, highlighting the vital need for transparent communication and cooperation across all stakeholders. The opportunity when done right?: The advancement of incremental innovations that can eventually transform a devastating disease into a manageable condition.